Credit Suisse Group set a $142.00 price target on Puma Biotechnology (NASDAQ:PBYI) in a research note published on Monday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on the company. Zacks Investment Research downgraded Puma Biotechnology from a hold rating to a sell rating in a research note on Monday. Citigroup reaffirmed a buy rating and issued a $164.00 target price on shares of Puma Biotechnology in a research note on Wednesday, January 3rd. ValuEngine downgraded Puma Biotechnology from a hold rating to a sell rating in a research note on Wednesday, January 3rd. BidaskClub downgraded Puma Biotechnology from a strong-buy rating to a buy rating in a research note on Tuesday, November 14th. Finally, Barclays reaffirmed a buy rating and issued a $122.00 target price (up from $103.00) on shares of Puma Biotechnology in a research note on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. Puma Biotechnology currently has a consensus rating of Buy and a consensus price target of $130.67.

Shares of Puma Biotechnology (NASDAQ PBYI) traded up $3.55 during mid-day trading on Monday, reaching $99.25. The company’s stock had a trading volume of 1,069,200 shares, compared to its average volume of 598,467. Puma Biotechnology has a 12 month low of $28.35 and a 12 month high of $136.90. The stock has a market cap of $3,720.00, a price-to-earnings ratio of -12.12 and a beta of 0.72.

Puma Biotechnology (NASDAQ:PBYI) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.50) by $0.43. The company had revenue of $6.10 million during the quarter, compared to analyst estimates of $3.78 million. During the same period last year, the business earned ($1.11) earnings per share. equities analysts expect that Puma Biotechnology will post -8.17 EPS for the current year.

In related news, insider Charles R. Eyler sold 1,322 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $105.46, for a total transaction of $139,418.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 21.10% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of PBYI. Schwab Charles Investment Management Inc. increased its position in shares of Puma Biotechnology by 3.4% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 123,380 shares of the biopharmaceutical company’s stock worth $10,784,000 after purchasing an additional 4,068 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Puma Biotechnology by 1.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 136,297 shares of the biopharmaceutical company’s stock worth $11,912,000 after purchasing an additional 2,072 shares during the last quarter. Legal & General Group Plc increased its position in shares of Puma Biotechnology by 12.8% during the 2nd quarter. Legal & General Group Plc now owns 10,490 shares of the biopharmaceutical company’s stock worth $918,000 after purchasing an additional 1,193 shares during the last quarter. Prudential Financial Inc. acquired a new stake in shares of Puma Biotechnology during the 2nd quarter worth about $302,000. Finally, Principal Financial Group Inc. acquired a new stake in shares of Puma Biotechnology during the 2nd quarter worth about $460,000. 96.00% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Puma Biotechnology (PBYI) Given a $142.00 Price Target by Credit Suisse Group Analysts” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.dailypolitical.com/2018/01/16/puma-biotechnology-pbyi-given-a-142-00-price-target-by-credit-suisse-group-analysts.html.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.